Good point. First line for 113 in ALK with brain mets would be great. That would get them the most market penetration. Brain mets are a huge concern for these patients and I am sure many doctors and patients would like to start with a 2nd generation drug that has efficacy there. As for pona in neurodegenerative diseases. I would expect they are doing preclinical work prior to planning any clinical testing. The Parkinson's indication might come first, PD trials do not require as much resources as Alzheimer's. If there is reason to believe they have a decent chance of sucess and they don't want to go it alone (for one reason or another) big pharma would be happy to foot the bill for a piece of the action. As far as their lack of experience in neurodegenerative disease is concerned, I don't see that as a problem. All they need are a few key hires. MO
News 
Market Data 
Discover 
